Maa: Armenia
Kieli: englanti
Lähde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
glimepiride
Denk Pharma GmbH & Co. KG
A10BB12
glimepiride
2mg
tablets
(30/3x10/) in blister
Prescription
Registered
2018-01-10
_Glimepiride Denk 2_ Tablet – oral use Antidiabetic agent Active substance: glimepiride Package leaflet: Information for the patient READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. – Keep this leaflet. You may need to read it again. – If you have any further questions, ask your doctor or pharmacist. – This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. – If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. WHAT GLIMEPIRIDE DENK 2 IS AND WHAT IT IS USED FOR 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE GLIMEPIRIDE DENK 2 3. HOW TO TAKE GLIMEPIRIDE DENK 2 4. POSSIBLE SIDE EFFECTS 5. HOW TO STORE GLIMEPIRIDE DENK 2 6. CONTENTS OF THE PACK AND OTHER INFORMATION 1. What Glimepiride Denk 2 is and what it is used for Glimepiride Denk 2 is an orally active blood sugar lowering drug. This drug belongs to a blood sugar lowering group of medicines called sulfonylureas. Glimepiride Denk 2 works by increasing the amount of insulin released from your pancreas. The insulin then lowers your blood sugar levels. Glimepiride Denk 2 is used to treat a certain form of diabetes (type 2 diabe - tes mellitus) when diet, physical exercise and weight reduction alone have not been able to control your blood sugar levels. 2. What you need to know before you take Glimepiride Denk 2 Do not take Glimepiride Denk 2 and tell your doctor if • you are allergic to glimepiride or certain other sulfonylureas (medicines used to lower your blood sugar such as glibenclamide) or sulfonamides (medicines for bacterial infections such as sulfamethoxazole) or any of the other ingredients of this medicine (listed in section 6) • you have insulin dependent diabetes (type 1 diabetes mellitus) • you have diabetic ketoacidosis (a complication of diabetes when your Lue koko asiakirja
1 S UMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Glimepiride Denk 2 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: glimepiride Each tablet contains 2 mg glimepiride. Excipients with known effect: Glimepiride Denk 2 contains lactose monohydrate and less than 1 mmol sodium (23 mg) per tablet. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet White, oblong, flat, uncoated tablet with facet and with breakline on one side. The tablets can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Glimepiride is indicated for the treatment of type 2 diabetes mellitus, when diet, physical exercise and weight reduction alone are not adequate. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For oral administration. The basis for successful treatment of diabetes is a suitable diet, regular physical activity as well as regular monitoring of blood and urine values. Antidiabetic agents or insulin cannot compensate if the patient does not keep to the recommended diet. POSOLOGY The dose is determined by the results of blood and urinary glucose determinations. The starting dose is 1 mg glimepiride a day. If sufficient metabolic control is achieved, this dose should be used for maintenance therapy. For the different dose regimens appropriate strengths are available. If metabolic control is unsatisfactory, the dose should be increased gradually, based on glycaemic situation, to 2, 3 or 4 mg glimepiride per day at intervals of about 1 to 2 weeks. A dose of more than 4 mg glimepiride per day gives better results only in exceptional cases. The maximum recommended dose is 6 mg glimepiride a day. 2 If patient’s metabolism is not adequately controlled with the maximum daily dose of metformin alone, concomitant therapy with glimepiride can be initiated. While maintaining the metformin dose, the glimepiride therapy is started with a low dose, and is then titrated up depending on the desired level of metabolic control up to the maximum daily dose. This com Lue koko asiakirja